Compare Cardinal Health Inc (CAH) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Huntington Bancshares Incorporated — how do they compare? Cardinal Health Inc trades at $224.88 (market cap $53.89B), while Huntington Bancshares Incorporated trades at $18.1 (market cap $36.18B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| CAH | HBAN | |
|---|---|---|
Market Cap | $53.89B | $36.18B |
Sector | Health | Financials |
52-Week High | $239.71 | $19.27 |
52-Week Low | $146.04 | $15.02 |
Enterprise Value | $58.87B | — |
Dividend Yield | 0.89% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Huntington Bancshares (HBAN) trades at $17.93, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, and maintains a net income margin of 25.13%. Recent news highlights expansion in Texas and a fintech partnership award. Analyst consensus is a Buy with a $20.25 price target, suggesting potential upside.
HBAN presents a favorable outlook with earnings growth potential, supported by strategic acquisitions and solid fundamentals. Risks include integration challenges from recent M&A and competitive pressures in regional banking. The stock's current valuation below consensus target indicates room for appreciation, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
